GlassScriptPhysician profile
Jonathan P Andrews
NPI 1134484942
$1,992.48
in general payments reported to CMS, 2019-2025
21 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $223 · 2021: $17.51 · 2023: $410 · 2024: $812 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $356.76 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $254.17 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $237.27 | 2019-2024 | Zepbound, Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $231.74 | 2020-2025 | Arexvy, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $222.21 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $153.24 | 2019-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $94.09 | 2024 | Veozah |
| Abbott Laboratories | $86.08 | 2023-2024 | Freestyle Libre 3 |
| Abbvie INC. | $71.97 | 2021-2025 | |
| Boston Scientific Corporation | $45.60 | 2024 | Wavewriter Alpha Prime 16 |
| Bayer Healthcare Pharmaceuticals INC. | $37.85 | 2023 | |
| Neurocrine Biosciences, INC. | $29.54 | 2024 | Ingrezza |
| Amarin Pharma, INC. | $29.02 | 2019-2020 | |
| Thea Pharma INC. | $21.90 | 2024 | Iyuzeh |
| Phathom Pharmaceuticals, INC. | $20.33 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $19.54 | 2019 | |
| Biogen, INC. | $19.11 | 2023 | Spinraza |
| Regeneron Healthcare Solutions, INC. | $18.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.52 | 2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $14.36 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.